75. The state of the industry

<p>Why do China and US have different government regulations? Why can’t we do business above the fray? </p> <p>These are just some of the struggles biopharma executives report impacting their business. Our guests are of the same view – the industry needs fixing.</p> <p>Yingke He, CEO and Co-Founder of Forecyte Bio, explains how China&#39;s industrialized experience is limited and in its early stages compared to the US.</p> <p>Listen to this episode to understand the industry tensions and areas showing promise. </p> <p><strong>Show notes</strong></p> <p>The Biopharma Resilience Index - <a href="https://www.cytivalifesciences.com/en/us/behind-biopharma/biopharma-resilience" target="_blank" rel="noopener noreferer">Biopharma Resilience | Cytiva (cytivalifesciences.com)</a></p> <p>Pessimists Archive - <a href="https://pessimistsarchive.org/" target="_blank" rel="noopener noreferer">Pessimists Archive</a></p> <p>Caesarean babies and their mother’s microbiome - <a href="https://www.newscientist.com/article/2378514-exposing-c-section-babies-to-vaginal-fluid-boosts-their-development/" target="_blank" rel="noopener noreferer">&#39;Vaginal seeding&#39; boosts the development of babies born by C-section | New Scientist</a></p> <p><em>Keywords</em>: talent, industry, manufacturing, collaboration, pandemic, therapies, challenges, government, regulators, biopharma resilience index, policies, solutions, companies, China, genomic medicine, cell and gene therapy.</p>